GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » EMIS Group PLC (LSE:EMIS) » Definitions » GF Value

EMIS Group (LSE:EMIS) GF Value : £13.87 (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is EMIS Group GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), EMIS Group's share price is £19.20. EMIS Group's GF Value is £13.87. Therefore, EMIS Group's Price-to-GF-Value for today is 1.38.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes EMIS Group is Data Out of Date, Use Caution.


EMIS Group  (LSE:EMIS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

EMIS Group's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=19.20/13.87
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EMIS Group GF Value Related Terms

Thank you for viewing the detailed overview of EMIS Group's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


EMIS Group (LSE:EMIS) Business Description

Traded in Other Exchanges
N/A
Address
Micklefield Lane, Fulford Grange, Rawdon, Leeds, GBR, LS19 6BA
EMIS Group PLC provides healthcare software and information technology services in the UK. The firm receives revenue from software licenses, hosting services, installation, training, and other support services. The company's main segments are Primary, Community and Acute Care, Community Pharmacy, and Patient. EMIS Group's community pharmacy software manages the dispensing process and keeps track of patient records and inventory.

EMIS Group (LSE:EMIS) Headlines

From GuruFocus

Emisphere Development Update

By Marketwired Marketwired 05-31-2018

EMISPHERE DEVELOPMENT UPDATE

By Marketwired Marketwired 04-06-2020

Emisphere Announces Leadership Changes

By Marketwired Marketwired 09-10-2019

Emisphere Amends License Agreement with Novo Nordisk

By Marketwired Marketwired 04-26-2018

ELIGEN B12 Receives “Amazon's Choice” Designation

By Marketwired Marketwired 05-30-2018

Emisphere Development Update

By Marketwired Marketwired 11-26-2018